A Myeloma Pioneer Sees More Innovation

Andrew D. Smith
Published: Monday, Mar 16, 2020
Kenneth C. Anderson, MD

Kenneth C. Anderson, MD

When Kenneth C. Anderson, MD, first arrived at Dana-Farber Cancer Institute in Boston, Massachusetts, 40 years ago, he immediately joined ongoing efforts to develop and test what would become the first generation of monoclonal antibodies, agents subsequently used for the diagnosis and treatment of B-cell malignancies. He was on the leading edge of a treatment revolution in multiple myeloma.

The treatment of myeloma has benefited from many advancements over the ensuing years, and Anderson remains at the forefront of discovery in this disease type. A 2014 winner of the Giants of Cancer Care® award in myeloma, Anderson is program director of the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber.

He is also cochair of the 4th Annual Live Medical Crossfire®: Hematologic Malignancies, to be held Saturday, July 11, 2020, at the InterContinental New York Times Square in New York. The 1-day conference gives oncologists and hematologists a practical overview of important developments in the myeloma treatment landscape.

"An Outstanding Investigator" 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication